ABBREVIATIONS BED = biological equivalent dose; CTCAE = Common Terminology Criteria for Adverse Events; CTV = clinical target volume; GTV = gross tumor volume; LC = local control; OS = overall survival; PFS = progression-free survival; PTV = planning treatment volume; RT = radiation therapy; SHR = subhazard ratio; SSRS = spine stereotactic radiosurgery. 33%] ). The actuarial 1-year OS and LC rates were 67% and 81%, respectively. Eighteen patients had a local relapse, which was more significantly associated with postoperative SSRS (p = 0.04). On multivariate modeling, receipt of postoperative SSRS neared significance for poorer LC (p = 0.06, subhazard ratio [SHR] 2.33), while only 2 covariates emerged as significantly correlated with LC: 1) biological equivalent dose (BED) > 48 Gy (vs BED ≤ 48 Gy, p = 0.006, SHR 0.21) and 2) single vertebral body involvement (vs multiple bodies, p = 0.03, SHR 0.27). Of the 18 local recurrences, 14 (78%) occurred at the margin, and while the majority of these cases relapsed within the epidural space, 4 relapsed within the paraspinal soft tissue. In addition, 1 relapse occurred out of field. Finally, the most common acute toxicity was fatigue (15 cases), with few late toxicities (4 insufficiency fractures, 3 neuropathies). CONCLUSIONS For metastatic sarcomas, SSRS provides durable tumor control with minimal toxicity. High-dose single-fraction regimens offer optimal LC, and given the infiltrative nature of sarcomas, when paraspinal soft tissues are involved, larger treatment volumes may be warranted.
S
arcomaS have a high propensity for distant metastasis. Approximately 30% of patients presenting with localized sarcomas will eventually develop distant disease, and about 10% of patients have metastases at the time of presentation. 7, 30 The most common site for metastasis is the lung parenchyma, with spinal disease developing in a smaller proportion of patients. However, sarcoma spinal metastases represent a dominant source of morbidity and negatively impact quality of life as a result of cancer-related, neuropathic, or mechanical pain; pathological fracture; and spinal cord compression. 8 Therefore, aggressive local therapy with either radiation therapy (RT) or surgical intervention is often needed to control symptoms, preserve function, and enhance local tumor control.
Spine stereotactic radiosurgery (SSRS) has become a widely adopted conformal method of delivering high, ablative doses of RT for metastatic spinal disease. Among all cancer types, SSRS offers a favorable risk-benefit profile while providing 1-year local control (LC) rates generally above 85%. 1, 3, 5, 13, 14, 23, 25, 29 However, there are limited data on the efficacy of SSRS for the treatment of metastatic sarcoma. Among the few published reports are inconsistent tumor control rates ranging between 51% and 88% at 1 year. 6, 10, 18, 19 Notably, the lower tumor control rates in this range are not dissimilar to the rates expected from conventional fractionation. 2, 10, 14, 16, 22 Therefore, if these outcomes truly reflect the course of sarcoma spinal metastases following SSRS, why is tumor control poorer for this histological entity?
Perhaps the explanation is related to the biology of sarcomas, or perhaps it is related to treatment delivery. There is an interesting philosophical and arguably incongruent difference in the therapeutic approach between highly conformal SSRS and the wide-margin, large-volume conventional fractions used for primary sarcomas. 9, 15, 27 Given the propensity of primary sarcomas to recur in the soft tissue when inadequate radiation field margins are used, it may be necessary to modify SSRS treatment fields for this histology in the metastatic setting. To better understand the efficacy of SSRS for metastatic sarcomas, we reviewed our experience to investigate tumor control outcomes and better characterize patterns of failure to aid in strategies for improved LC.
Methods

Patients
We identified 48 consecutive patients with 66 sarcoma spinal metastases treated with SSRS at the University of Texas MD Anderson Cancer Center during the period between 2002 and 2013. Thirty-five of the lesions (53%) had been treated in 3 institutional Phase I/II trials evaluating single-and multifraction SSRS for spinal metastases. 5, 11, 12 After obtaining approval from the institutional review board, we extracted patient, tumor, and outcome characteristics from the medical records for the entire group.
Treatment
All patients were treated using CT-guided intensitymodulated SSRS using the CT-on-rails EXaCT targeting system or Trilogy treatment delivery system with on-board cone-beam CT (Varian Medical Systems), as previously described. 4, 21 After patients were immobilized in an Elekta BodyFix stereotactic body frame (Elekta) and aligned using a CT-on-rails (GE Healthcare) or cone-beam CT, treatments were delivered typically using a 9-field stepand-shoot intensity-modulated radiation treatment plan. Each procedure was monitored by the treating radiation oncologist and a dedicated radiation physicist to verify target positioning and quality assurance.
Metastatic spinal tumors were treated with various doses and fractionations. Given that the first institutional protocols established safety and efficacy, the regimens investigated were more conservative. However, more contemporary patients were treated with standardized regimens based on tumor radiosensitivity and previous RT. Contouring of the gross tumor volume (GTV) and clinical target volume (CTV) was consistent with recent consensus guidelines for SSRS (not specific to histology). 9 The GTV was defined as visible tumor on an MR image fused with the planning CT scan, and the CTV, which contains the GTV, was defined as at-risk contiguous bone marrow or soft-tissue margin in cases with paraspinal extension of disease. The planning treatment volume (PTV) was defined with no margin to the CTV. The dose was commonly normalized between the 80% and 90% isodose line, 21 so that the prescription line enclosed the PTV, except near the spinal cord as necessary. Postoperative SSRS target delineation began with fusion of the preoperative MR image to the planning CT scan. The GTV was defined as any residual disease and/or the postoperative bed. The CTV was defined as the GTV with contiguous bone marrow space and any additional postoperative bed at risk for harboring microscopic disease. Additional radiation details and outcomes of postoperative SSRS were recently published by Tao and colleagues. 26 To account for the various fractionation schemes, a biological equivalent dose (BED) was calculated for the prescription based on the a/b value of 10 Gy for tumor effect.
Follow-Up and Relapses
The median follow-up for the entire cohort was 19 months (range 1-121 months) and for all living patients 31 months (range 10-121 months). Acute (defined as less than 3 months) and long-term toxicities were prospectively recorded for patients treated on protocol (53%); otherwise, toxicities were retrospectively graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
Patients were seen every 3 months for physical examination and MRI of the spine to assess for radiological tumor recurrence. Local recurrences were defined as radiological evidence of progression as identified by the reading radiologist. After confirmation by the radiation oncologist, local recurrences were subclassified based on anatomical location of the tumor recurrence (epidural space vs paraspinal) and its proximity to isodose lines. Infield relapses were defined as being entirely encompassed within the 95% isodose line, whereas marginal relapses occurred partially or fully in the penumbra commonly between the 20% and 95% prescription isodose lines.
Statistical Analysis
Descriptive statistics were used to evaluate baseline characteristics, and categorical data were analyzed using Fisher's exact test and chi-square analyses. Survival times were calculated from the start date of SSRS to the first occurrence of the considered event. The Kaplan-Meier method was used to estimate rates of overall survival (OS) and LC. Log-rank tests were applied to assess for equality across groups.
The Cox proportional-hazards model was used for univariate and multivariate analyses of OS. Multivariate assessment was done by backward elimination, with all factors with a p ≤ 0.25 on univariate analysis included in the assessment. Estimated hazard ratios were reported when significant (p ≤ 0.05). For LC and progression-free survival (PFS), a competing risk analysis was performed using the Fine and Gray method; death was treated as a competing risk. Estimated subhazard ratios (SHRs) were reported when significant (p ≤ 0.05). A 2-sided 5% significance level was used for analysis. StataCorp statistical software version 13.1 was used for data analysis.
Results
Cohort Characteristics
Patient, tumor, and treatment characteristics are summarized in Table 1 . The overall median age was 53 years (range 17-85 years), and 53% of the patients were female. The most commonly treated sarcoma histology was leiomyosarcoma (28 [42%]), followed by epithelioid sarcoma (9 [14%]) and malignant fibrous histiocytoma/unclassified pleomorphic sarcoma (8 [13%] ).
At presentation, the majority of tumors were Bilsky Grade 0-1b (42 [64%]). 2 However, patients with higher degrees of cord compression (Bilsky Grades 1c-3) at presentation were more likely to undergo surgery (p < 0.001) than the patients with lower Bilsky grades. Therefore, at A higher proportion of patients who had been treated with postoperative SSRS experienced local recurrence compared with those who had received definitive SSRS (45% vs 18%, p = 0.04). There were no other significant differences between patients with local relapse and those without, including Bilsky grade at the time of SSRS (p = 0.67; Table 1 ).
Patterns of Disease Recurrence
Nineteen patients (29%) developed local or adjacent vertebral body relapse-local only, 8 patients; in both locations, 10; and in the adjacent vertebral body alone, 1. The median time to any treatment failure was 8 months (range 1-71 months).
Actuarial 1-and 3-year LC rates were 81% and 61%, respectively (Fig. 1) . Eighteen patients (27%) had local disease recurrence with a median time of 8 months to failure (range 1-71 months). On multivariate modeling, with death as a competing risk factor, the 2 covariates independently associated with higher LC rates were single vertebral body involvement (vs multiple vertebral bodies, p = 0.03, SHR 0.27, 95% CI 0.08-0.85) and BED > 48 Gy (vs BED ≤ 48 Gy, p = 0.006, SHR 0.21, 95% CI 0.07-0.64; Table 2 ).
To better define patterns of failure, we evaluated local recurrences as infield (3 [17%] ), at the margin within the isodose penumbra (14 [78%] ), or out of field (1 [6%]; Table  3 ). Among the 3 cases of infield failures, 2 (67%) had leiomyosarcoma histology. Among the 14 cases of marginal local recurrences, 10 (71%) occurred within the epidural space; the other 4 cases had marginal recurrences within the paraspinal musculature. Retrospective review of these latter cases-3 leiomyosarcoma, 1 alveolar soft part sarcoma-revealed that the CTVs were probably too conservative. For the 1 out-of-field recurrence, retrospective review of pretreatment imaging revealed that the tumor outside the delineated target might have been present prior to treatment.
Overall Survival
Actuarial 1-and 3-year OS rates were 67% and 26% (Fig. 1) , respectively, with a median OS of 17 months (range 1-121 months). When variables were assessed using a backward elimination technique, 3 covariates emerged 
Toxicity
Based on the CTCAE version 4.3, there were 35 treatment-related acute toxicities (53%), all of which were either Grade 1 or 2 (no Grade 3 or 4; Table 4 ). The most common acute toxicity was fatigue (15 cases [23%] of Grade 1, 5 cases [8%] of Grade 2). Gastrointestinal toxicities were also relatively common (15 [23%] ). There were 6 (9%) treatment-related instances of nausea, and the midspine (T5-L2) was the SSRS target in all of these cases. Additionally, there were 6 (9%) episodes of dysphagia (4 cases of Grade 2); 5 of those cases had received SSRS to the cervical spine. Pain flares were uncommon but occurred in 3 patients (4%) after SSRS, with 2 cases occurring in patients who had received single-fraction SSRS (p = 0.48) Late toxicities were less common. There were 4 insufficiency fractures (6%) occurring at a median time of 13 months post-SSRS (range 6-23 months), and they were not associated with single-versus multifraction SSRS regimens (p = 0.36). While 3 of the insufficiency fractures were relatively asymptomatic, 1 case was particularly concerning, causing severe spinal stenosis and associated myelomalacia, though notably without neuropathies. There were 
Discussion
Local management of sarcoma spinal metastases is challenging given the limited definitive surgical options, the radioresistant nature of this tumor, and the difficulty in delivering meaningful ablative doses using conventional RT. Therefore, the use of highly conformal high-dose SSRS may offer a way to improve outcomes for patients with metastatic sarcoma to the spine. In the current series, we observed favorable local tumor control using SSRS. However, patients who received SSRS after surgery had a higher rate of local recurrence, and a low BED was associated with poorer tumor control. According to our analysis of failure patterns, the majority of local failures were marginal recurrences, commonly occurring in the epidural space (Fig. 2) . Importantly, however, several marginal recurrences probably happened because of insufficient treatment volume, particularly when there was soft-tissue extension. Despite relatively high rates of LC and a favorable toxicity profile associated with SSRS, OS remains poor given the limited systemic options for treating metastatic sarcomas.
With the wide adoption of SSRS, 20 multiple studies have reported high LC rates above 85% among all disease histologies. 3, 5, 13, 14, 23, 25, 29 Among the few investigators specifically treating sarcomas, however, the LC rates are not as consistent. 6, 10, 19 In the present study, we observed a favorable 1-year LC rate of 81%, which is lower than the rate for other histologies but consistent with the rates in 2 recent series reporting 1-year control rates of 88% and 78%. 6, 10 However, authors from the Cleveland Clinic observed a notably lower radiographic control rate (51% at 12 months). 19 While this series by Miller and colleagues is a bit of an outlier, it does highlight the difficulty in treating these spine lesions.
Sarcomas have historically been viewed as a relatively radioresistant histology, which underscores the importance of RT dose for local tumor control (Fig. 3) . In a study by Kepka and colleagues, higher conventional RT doses were associated with improved LC of gross primary disease (< 63 Gy, 22% vs ≥ 63 Gy, 60%; p = 0.02). 17 In our study, we observed that a BED > 48 Gy (Gy/fractions: 24/1, 27/3, 18/1) was significantly associated with improved LC on univariate analysis (p = 0.04, SHR 0.33). Chang and colleagues also reported that higher RT doses were associated with improved 2-year LC rates (> 22 Gy, p = 0.03). 6 Perhaps lower RT doses (median 16 Gy in 1 fraction, range 10-16 Gy) explain the poorer LC rates observed by Miller and colleagues (51% at 1 year), 19 compared with our typical dose of 24 Gy in 1 fraction or the median dose of 24 Gy reported by authors at Memorial Sloan Kettering Cancer Center (1-year LC 88%). 10 One interesting observation from our study is the higher rate of local recurrence in patients treated with postoperative SSRS than in those definitively treated with SSRS alone (45% vs 18%, p = 0.04). This translated into a lower, though not statistically significant, 1-year LC rate among postoperative SSRS patients (71% vs 87% for definitive SSRS, p = 0.07, SHR 2.31), with the definitive SSRS patients attaining an LC rate similar to our recently published rate (88%) among 332 spinal lesions. 3 The high rate of local relapse following postoperative SSRS for sarcomas was also recently observed by Tao and colleagues, 26 who reported a 1-year LC rate of 58% for sarcoma histologies compared with 88% for nonsarcomatous histologies (p = 0.025). Several factors may contribute to a higher relapse rate among postoperative SSRS patients including fractionation, radiation dose, risk of surgical seeding, or radiobiological principles such as devascularization of the tissues resulting in less oxygen delivery.
Fractionation has been associated with LC outcomes of SSRS according to a study by Folkert and colleagues, in which the authors found single-fraction SSRS to be the only factor associated with LC on multivariate analysis (p = 0.03, HR 0.35). 10 In contrast, most of the patients in our study who received postoperative SSRS were treated with multifraction regimens (17 [77%] of 22), commonly 27 Gy in 3 fractions (13 [76%] of 17). Interestingly, the 27 Gy in 3 fractions that we deliver postoperatively has a BED of 51 Gy, which is lower than what would be prescribed in the postoperative primary sarcoma setting and is far below the threshold for controlling gross disease. 17 Therefore, while fractionation and the delivered BED may contribute to a higher relapse rate among postoperative SSRS sarcoma patients, the benefits of escalating treatment must be weighed against the risks of injury.
Another complicating feature of sarcoma is its infiltrative, locally aggressive growth patterns. This has treatment implications given the highly conformal delivery of SSRS with no consensus recommendations for treating infiltrating paraspinal disease. Therefore, we performed an analysis of failure patterns to better understand the association between target volume and local recurrences. Of the 18 local recurrences, 14 were classified as marginal failures. Not surprisingly, many of these local failures occurred in the epidural space, which is consistent with previous reports showing that adequate coverage of tumors involving the epidural space close to the spinal cord (within 2-5 mm) is challenging. 3, 5, 24 However, there were several local relapses that might have been avoided if larger treatment volumes had been used. We observed 4 marginal recurrences that all arose in the paraspinal soft tissue. At the time of treatment planning, there were probably inadequate CTV expansions applied to these cases to account for the microscopically invasive nature of sarcomas. Better definition of appropriate treatment volumes is particularly important given the high proportion of sarcoma patients who have paraspinal extension; in a report by Bilsky and colleagues, nearly 70% of the patients presenting with bone involvement also had soft-tissue extension. 2 Similarly, Miller and colleagues reported 60% of cases with paraspinal extension. 19 They also found that involvement of the posterior elements was associated with radiographic failure (p = 0.04, HR 2.16), which may also be related to paraspinal extension. Given the relatively restrictive space for growth within the posterior elements, metastatic deposits tend to erode through the bony cortex and extend into the paraspinal space. If adequate CTV expansions are not applied, local tumor control is less likely.
Several years ago the International Spine Radiosurgery Consortium published a recommendation for guidance on SSRS contouring. 9 While it expressly recommended no extraosseous CTV expansion for bone-only disease, there were no specific guidelines for coverage of paraspinal extension of disease or paraspinal metastases. Alternatively, if we examine the guidelines for target delineation of extremity sarcomas, 2 consensus statements recommend a 3-to 4-cm longitudinal expansion of the GTV and a 1.5-cm radial expansion. 15, 27 These recommendations are based on historical pathological studies, including one showing that 60% of cases with satellite tumor cells outside the primary sarcoma tumor were within 1 cm, whereas 40% were within 1-4 cm. 28 Therefore, if we extrapolate from the available literature, for sarcomas metastatic to vertebral bodies that erode through the cortex into the paraspinal soft tissue, we recommend considering a larger radial CTV expansion (perhaps 1.5 cm) into soft tissue since this type of growth may be less longitudinally infiltrative along fascial planes. However, perhaps sarcomas metastatic directly to the paraspinal tissues warrant target delineation more similar to primary sarcomas with a generous longitudinal CTV expansion along the paraspinal musculature.
This study provides additional evidence of durable LC rates using SSRS for sarcoma metastases and, importantly, contributes a unique pattern-of-failure analysis to help reconcile the 2 vastly different RT paradigms. However, as with any retrospective analysis, there are inherent limitations when interpreting the results. First, while this study represents a relatively large series, considering the paucity of data for SSRS to sarcoma metastases, the number of patients and subsequent local recurrences are few, which limits the robustness of the analysis. Second, this study does incorporate patients enrolled in our early institutional trials, which may have treated patients more conservatively than is our current practice. Third, while about half of the patients in the current study were followed prospectively, some of the toxicity data were retrospectively extracted. The most commonly observed acute toxicity was fatigue (23%), and there were no Grade 3 toxicities; Folkert and colleagues reported similar acute toxicities. 10 We also observed few late toxicities (4 compression fractures, 3 neuropathies), but we acknowledge the difficulty in retrospectively identifying treatment-related side effects. 
Conclusions
Spine stereotactic radiosurgery for sarcoma metastases is a viable option for providing durable LC with minimal toxicity. According to our data and the available literature, doses ≥ 22 Gy in a single fraction provide optimal tumor control.
6,10 Additionally, we observed a higher rate of local relapse in postoperative SSRS cases, which is also probably attributable to the RT dose and fractionation. In our analysis of patterns of failure, we found that the majority of relapses occurred within the epidural canal. However, in a small proportion of cases, more generous treatment volumes could minimize the risk of relapse. Specifically, in cases with paraspinal extension eroding through bone cortex, we recommend considering a larger CTV expansion (perhaps 1.5 cm) into the soft tissue, which is extrapolated from existing sarcoma consensus guidelines. For patients who have paraspinal metastases, more generous longitudinal expansions are probably warranted. In our continued pursuit of improved SSRS target delineation and conformality, we should remember the biological behavior of individual cancer types and the principles by which they shape our treatment volumes.
